Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy
| Autor: | Ryan P. Smith, Ronald M. Benoit, Joshua L. Rodríguez-López, Michael D. Schad, Ankur K. Patel, Sushil Beriwal, Christopher J. Houser, Zachary D. Horne |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Biochemical recurrence medicine.medical_specialty medicine.medical_treatment Brachytherapy Urology 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Median follow-up medicine Humans Radiology Nuclear Medicine and imaging External beam radiotherapy Retrospective Studies business.industry Prostatic Neoplasms Androgen Antagonists Prostate-Specific Antigen medicine.disease Oncology Cesium Radioisotopes 030220 oncology & carcinogenesis Cohort business Prostate brachytherapy Calcification |
| Zdroj: | Brachytherapy. 20:859-865 |
| ISSN: | 1538-4721 |
| DOI: | 10.1016/j.brachy.2021.03.013 |
| Popis: | Baseline intraprostatic calcification (IC) has been shown to be associated with a higher rate of biochemical recurrence (BCR) in men treated with iodine-125 prostate brachytherapy (PB). We evaluated this association in a cohort of men treated with cesium-131 PB.We retrospectively reviewed the charts of all low- and intermediate-risk prostate cancer patients treated with cesium-131 PB +/- external beam radiotherapy (EBRT) at our institution from 2/2011 to 7/2018. Patients with24 months of follow up or those who received androgen deprivation therapy were excluded. Baseline IC status (defined as one or more ICs ≥ 5 mm) was determined on post-PB CT scans. Cox analysis was used to assess predictors of BCR and Kaplan-Meier survival curves were calculated.Two hundred and sixteen low- and intermediate-risk prostate cancer patients treated with cesium-131 PB +/- EBRT were included. Median follow up was 56.9 months (range 24.1-111.4). Overall, 76 (35.2%) patients had baseline IC and 140 (64.8%) did not. Baseline disease characteristics did not differ significantly between groups. On univariate Cox analysis, only risk group (p = 0.047) and initial PSA (p = 0.016) were significant predictors of BCR, whereas baseline IC was not (p = 0.11). The 5-year BCR-free survival in patients with versus without baseline IC was 97.7% versus 93.8% (p = 0.405), respectively.In a cohort of low- and intermediate-risk prostate cancer patients treated with cesium-131 PB, the rate of BCR in men with baseline IC was low and baseline IC was not associated with a higher risk of BCR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|